What are the most promising avenues for medtech investors? That was the question discussed by a panel of entrepreneurs and venture investors at the 2012 CONVERGE Summit for Healthcare Innovation.
It seems that medical product design could become dominated by software. Echoing the conference’s overall theme of data, the big players are looking for digital solutions and the potential for very sizeable markets. They don’t want to venture risk in manufacturing operations. They’re looking for opportunities in which software is the key element in delivering value. They also want companies that are equipped with strong IP or other elements that create barriers to entry for competitors.
Yet there are still those who are willing to take a chance on the founders of small start-ups motivated by a passion to fix a negative experience they’ve had within the healthcare system.
Overall, the feeling was that this is a golden age for lifescience investing. Where there’s disruption there’s opportunity.